Trial
NCT00645229
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators
—
Condition
Schizophrenia
Intervention
Ziprasidone
Why stopped
Please see Detailed Description for termination reason.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-21